(SF Business Times subscription required.)
A bounty of new drugs from the labs of Bay Area companies could win Food and Drug Administration approval in the next few months.
At least 10 drugs — from an obesity treatment to cancer drugs — are candidates for FDA approval by the end of June. Industry observers said they didn’t know how that number compares with any previous six-month period.
One thing is sure: After the economic downturn pushed many investors away from the capital-intensive drug-development business, the cadre of potential new drugs represents a victory of sorts. Many drug developers — especially smaller ones — have carried their drugs within sight of the finish line by sheer will or grit.